The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Ye, Zhize; Hu, Jinyu; Wang, Jing; Liu, Yanan; Hu, Guoxin; Xu, Ren-ai

doi:10.1016/j.cbi.2023.110398

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To dilute oxycodone to a final concentration of 2 mg/mL before injection, we used saline solution. At 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8, and 10 h after injection, we collected blood samples from the tail vein as previously described ( Ye et al, 2023 ). Each sample was centrifuged at 13,000 rpm for 10 min, and 100 μL of the supernatant was mixed with 20 μL midazolam (200 ng/mL) and 200 μL acetonitrile.…”

Section: Methodsmentioning

confidence: 99%

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism

Zhou,

Ye,

et al. 2023

PeerJ

Self Cite

View full text Add to dashboard Cite

This study aimed to investigate the interactions between icotinib/apatinib and oxycodone in rats and to unveil the underlying mechanism. An ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to determine oxycodone and its demethylated metabolite simultaneously. In vivo, Sprague–Dawley (SD) male rats were administered oxycodone with or without icotinib or apatinib. Blood samples were collected and subjected to UPLC-MS/MS analysis. An enzyme incubation assay was performed to investigate the mechanism of drug–drug interaction using both rat and human liver microsomes (RLM and HLM). The results showed that icotinib markedly increased the AUC(0–t) and AUC(0–∞) of oxycodone but decreased the CLz/F. The Cmax of oxycodone increased significantly upon co-administration of apatinib. In vitro, the Km value of oxycodone metabolism was 101.7 ± 5.40 μM and 529.6 ± 19.60 μM in RLMs and HLMs, respectively. Icotinib and apatinib inhibited the disposition of oxycodone, with a mixed mechanism in RLM (IC50 = 3.29 ± 0.090 μM and 0.95 ± 0.88 μM, respectively) and a competitive and mixed mechanism in HLM (IC50 = 22.34 ± 0.81 μM and 0.48 ± 0.05 μM, respectively). In conclusion, both icotinib and apatinib inhibit the metabolism of oxycodone in vitro and in vivo. Therefore, the dose of oxycodone should be reconsidered when co-administered with icotinib or apatinib.

show abstract

Section: Methodsmentioning

confidence: 99%

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism

Zhou,

Ye,

et al. 2023

PeerJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furanocoumarins in P. corylifolia interact with CYP3A4, which can alter pharmacokinetics and pharmacodynamics. Pioneering research revealed that resveratrol could increase plasma exposure to tofacitinib by impeding CYP3A4 enzyme (Ye et al, 2023). Tofacitinib used with moderate or severe renal and hepatic Frontiers in Pharmacology frontiersin.org impairment must now be adjusted to 5 mg per day orally (Vyas et al, 2013).…”

Section: Enzymementioning

confidence: 99%

Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Wang,

Zhou,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

This work aimed to explore the mechanisms underlying the interaction of the active furanocoumarins in P. corylifolia on tofacitinib both in vivo and in vitro. The concentration of tofacitinib and its metabolite M8 was determined using UPLC-MS/MS. The peak area ratio of M8 to tofacitinib was calculated to compare the inhibitory ability of furanocoumarin contained in the traditional Chinese medicine P. corylifolia in rat liver microsomes (RLMs), human liver microsomes (HLMs) and recombinant human CYP3A4 (rCYP3A4). We found that bergapten and isopsoralen exhibited more significant inhibitory activity in RLMs than other furanocoumarins. Bergapten and isopsoralen were selected to investigate tofacitinib drug interactions in vitro and in vivo. Thirty rats were randomly allocated into 5 groups (n = 6): control (0.5% CMC-Na), low-dose bergapten (20 mg/kg), high-dose bergapten (50 mg/kg), low-dose isopsoralen (20 mg/kg) and ketoconazole. 10 mg/kg of tofacitinib was orally intervented to each rat and the concentration level of tofacitinib in the rats were determined by UPLC-MS/MS. More imporrantly, the results showed that bergapten and isopsoralen significantly inhibited the metabolism of tofacitinib metabolism. The AUC(0-t), AUC(0-∞), MRT(0-t), MRT(0-∞) and Cmax of tofacitinib increased in varying degrees compared with the control group (all p < 0.05), but CLz/F decreased in varying degrees (p < 0.05) in the different dose bergapten group and isopsoralen group. Bergapten, isopsoralen and tofacitinib exhibit similar binding capacities with CYP3A4 by AutoDock 4.2 software, confirming that they compete for tofacitinib metabolism. P. corylifolia may considerably impact the metabolism of tofacitinib, which can provide essential information for the accurate therapeutic application of tofacitinib.

show abstract

“…The mechanisms of action of RES involve inducing tumor cell apoptosis via multiple pathways, inhibiting proliferation, migration, and invasion, and enhancing the drug efficacy while reducing toxicity when used in combination with chemotherapy or targeted drugs. RES exerts its anticancer functions by regulating signaling pathways, such as Wnt/β-catenin, Hedgehog, mitogen-activated protein kinase (MAPK), and nuclear factor kappa B (NF-κB) ( Xie et al, 2023 ; Ye et al, 2023 ). In this review, we examine the anticancer mechanisms and targets of RES in common gynecological tumors, aiming to provide a new theoretical basis for treatment.…”

Section: Introductionmentioning

confidence: 99%

Advances in the role of resveratrol and its mechanism of action in common gynecological tumors

Yang,

Meng,

Zhang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

The incidence of common gynecological malignancies remains high, with current treatments facing multiple limitations and adverse effects. Thus, continuing the search for safe and effective oncologic treatment strategies continues. Resveratrol (RES), a natural non-flavonoid polyphenolic compound, is widely found in various plants and fruits, such as grapes, Reynoutria japonica Houtt., peanuts, and berries. RES possesses diverse biological properties, including neuroprotective, antitumor, anti-inflammatory, and osteoporosis inhibition effects. Notably, RES is broadly applicable in antitumor therapy, particularly for treating gynecological tumors (cervical, endometrial, and ovarian carcinomas). RES exerts antitumor effects by promoting tumor cell apoptosis, inhibiting cell proliferation, invasion, and metastasis, regulating tumor cell autophagy, and enhancing the efficacy of antitumor drugs while minimizing their toxic side effects. However, comprehensive reviews on the role of RES in combating gynecological tumors and its mechanisms of action are lacking. This review aims to fill this gap by examining the RES antitumor mechanisms of action in gynecological tumors, providing valuable insights for clinical treatment.

show abstract

The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Cited by 9 publications

References 17 publications

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism

Effect of P. corylifolia on the pharmacokinetic profile of tofacitinib and the underlying mechanism

Advances in the role of resveratrol and its mechanism of action in common gynecological tumors

Contact Info

Product

Resources

About